Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Aires thérapeutiques
  • Ressources
Campus
  • Aires thérapeutiques
  • Ressources
View Full Results

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

When to treat

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.1,2

Explorer

Pooled analysis: Interventional and observational studies

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.1

Explorer

Overview of cGvHD

Explorer

Actors

Explorer

Immunology mechanism

Explorer

Effect of cGVHD

Explorer

cGVHD criteria

Explorer

Guidelines

Explorer

What is Toujeo?

Explorer

How to Use Toujeo®

Explorer

Atopic dermatitis pathophysiology: type 2 inflammation & cytokines

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

Explorer

Living with T1D for 25 Years: Philippe's Inspiring Journey

At the dawn of his fifties, Philippe has tamed the diabetes he has lived with for over 25 years, along with his initial fear of injections. For him, this disease represents "a turning point, not an end." He leads a life "like everyone else," multiplying passions and fully enjoying every moment.

Explorer